Incyte Corp. (INCY)
NASDAQ: INCYHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 111.97 -1.30%
INCY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $22.99B
- P/E (TTM)
- 14.45
- Forward P/E
- 12.97
- EPS (TTM)
- $7.85
- Dividend yield
- None
- 52-week range
- 82.82 – 132.60
- Day range
- 112.82 – 115.49
- Volume / Avg
- 1.27M / 1.63M
- Beta
- —
- Shares outstanding
- 202.70M
- Next earnings
- Oct 27, 2026
52-week range
INCY stock today
Shares of Incyte (INCY) finished higher on Oct 7 at $113.44, a gain of 0.63% or $0.71 per share, versus the S&P 500's 0.22% decline. Shares are 14.4% below their 52-week high of $132.60, set on Jul 28, 2026 and 37.0% above the 52-week low of $82.82, in the middle of the past year's range. INCY is up 14.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 30.1%.
At 14.5x trailing earnings, Incyte trades below the peer-group median of 59.8x. Its forward P/E of 13.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 27; analysts expect EPS of -$3.87.
Summary generated from market data by MetaCap's automated system. Methodology
About Incyte
Company profileIncyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Mr. William J. Meury
- Headquarters
- Wilmington, DE
- Employees
- 2,844
- Website
- incyte.com
Financial highlights
Full financialsIn fiscal 2025, Incyte generated $5.14 billion in revenue, up 21.2% from fiscal 2024, its 14th consecutive year of revenue growth. Net income was $1.29 billion (+3845.0% year over year), for a net margin of 25.0% versus a median of 10.0% in the prior 5 years. Gross margin was 92.8% (up from 92.6%) and operating margin 29.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $5.14B | $4.24B | $3.70B | $3.39B | $2.99B |
| Growth | +21.22% | +14.76% | +8.87% | +13.67% | +11.98% |
| Net income | $1.29B | $32.62M | $597.60M | $340.66M | $948.58M |
| EPS (diluted) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 |
Analyst forecast
ForecastConsensus (28 analysts)
buy
Avg. price target
$128.92+13.65%
- Strong buy 2
- Buy 10
- Hold 15
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $-3.87
- Last reported (Q1 2026)
- Apr 28, 2026
- EPS actual vs est.
- $1.47 vs —
INCY news
All INCY newsIncyte peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MEDPMedpace Holdings Inc. | 604.25 | +0.22% | $16.87B | vs INCY |
| CRLCharles River Laboratories International Inc. | 300.30 | -1.53% | $14.46B | vs INCY |
| ICLRICON plc | 164.08 | +1.48% | $12.66B | vs INCY |
| IQVIQVIA Holdings Inc. | 258.11 | -0.72% | $42.48B | vs INCY |
| ABSIAbsci Corporation | 9.22 | -10.22% | $1.58B | vs INCY |
| OABIOmniAb Inc. | 4.56 | +4.83% | $662.98M | vs INCY |
| NRCNRC Health | 20.19 | +0.55% | $446.59M | vs INCY |
| MXCTMaxCyte Inc. | 1.04 | -4.59% | $107.33M | vs INCY |
Indexes, lists and sector
Index membership
Incyte stock FAQ
What is Incyte's stock price today?
INCY last traded at $113.44 as of Oct 7, 4:00 PM EDT, up 0.63% on the day. Prices are delayed at least 15 minutes.
Does Incyte pay a dividend?
No. Incyte does not currently pay a regular cash dividend.
When is Incyte's next earnings date?
Incyte is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $-3.87.
What is INCY's P/E ratio?
INCY trades at a trailing P/E ratio of 14.45 and a forward P/E of 12.97, compared with a median of 59.8 for its closest peers.
Is Incyte in the S&P 500?
Yes. Incyte (INCY) is a constituent of the S&P 500 index.
Who is Incyte's CEO?
Mr. William J. Meury is the chief executive officer of Incyte Corp., which has about 2,844 employees.
Has INCY ever split its stock?
Yes. The most recent INCY stock split was a 2-for-1 split on Sep 1, 2000, one of 2 splits on record.